GlassScriptPhysician profile
Allan O Rosenfield
NPI 1255320750
$1,114.92
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $99.08 · 2021: $290 · 2022: $475.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $149.12 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $98.11 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.09 | 2022 | |
| Eisai INC. | $76.85 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $69.66 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $67.55 | 2019 | |
| Abbvie INC. | $54.62 | 2021-2022 | |
| Glaxosmithkline, LLC. | $45.93 | 2022 | |
| Novartis Pharmaceuticals Corporation | $44.89 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $42.58 | 2019-2022 | |
| Biogen, INC. | $40.22 | 2021 | |
| Lilly USA, LLC | $38.92 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.47 | 2022 | |
| Avanir Pharmaceuticals, INC. | $34.96 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $34.38 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $32.27 | 2020 | |
| Redhill Biopharma INC. | $20.88 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.70 | 2022 | |
| Janssen Biotech, INC. | $17.44 | 2022 | |
| Eyevance Pharmaceuticals LLC | $17.39 | 2021 | |
| Csl Behring | $17.14 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $15.77 | 2022 | |
| Boston Scientific Corporation | $15.22 | 2019 | |
| Dexcom, INC. | $14.01 | 2021 | |
| Amgen INC. | $13.25 | 2019 | |
| Allergan, INC. | $12.50 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allan Rosenfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.